ArticleCytoJournal2026
Tumor-associated macrophage-derived chemokine ligand 5 regulates the Hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway to promote breast cancer invasion and migration.
Article in CytoJournal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Tumor-associated macrophages (TAMs) are important components of the breast cancer (BC) microenvironment that contributes to tumor progression by secreting cytokines. Chemokine ligand 5 (CCL5) expression is upregulated in BC, but the specific mechanism of TAM-derived CCL5 in BC microenvironment remains elucidated. This article aims to explore the role of TAM-derived CCL5 in the progression of BC. Material and Methods: M2-type TAMs were induced from Tohoku Hospital Pediatrics-1 (THP-1) monocytes. CCL5 expression in TAM cells was evaluated. The biological effects of recombinant or TAM-derived CCL5 on ZR-75-30 cells were examined using proliferation, migration, invasion assays, and epithelial-mesenchymal transition (EMT) markers. CCL5 was silenced in TAMs and hypoxia-inducible factor-1α (HIF-1α) was overexpressed to explore the downstream signaling pathway. Results: CCL5 expression was significantly increased in TAMs compared with that in BC cells ( Conclusion: TAM-derived CCL5 plays an oncogenic role in BC by regulating HIF-1α/VEGF pathway-mediated malignancy and angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.